<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandeep Gurbuxani, MBBS, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bob Lowenberg, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid lineage. Acute promyelocytic leukemia (APL) is a biologically and clinically distinct variant of AML. APL was classified as AML-M3 in the older French-American-British (FAB) classification system and is currently classified as acute promyelocytic leukemia with t(15;17)(q24.1;q21.2);<em>PML::RARA</em> [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/86098.html" rel="external">"Acute myeloid leukemia: Classification"</a>.)</p><p>APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from a characteristic coagulopathy. It is critical to start treatment with a differentiation agent (eg, <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a>) without delay as soon as the diagnosis is suspected based on cytologic criteria, and even before definitive cytogenetic or molecular confirmation of the diagnosis has been made.</p><p>The clinical features, diagnosis, and prognosis of APL in adults will be reviewed here. The following other topics are covered separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Molecular biology of APL (see  <a class="medical medical_review" href="/d/html/4523.html" rel="external">"Molecular biology of acute promyelocytic leukemia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of APL (see  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a> and  <a class="medical medical_review" href="/d/html/4505.html" rel="external">"Treatment of relapsed or refractory acute promyelocytic leukemia in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features, diagnosis, and prognosis of AML in adults (see  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"</a> and  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a> and  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities"</a>)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Depending on geographic variations, APL accounts for 5 to 20 percent of cases of acute myeloid leukemia (AML); there appear to be approximately 600 to 800 new cases per year in the United States [<a href="#rid3">3,4</a>]. With respect to the incidence of APL among ethnic groups, contradictory data regarding a presumed higher incidence of APL in persons from Mexico, Central and South America, Italy, and Spain have been reported in the literature [<a href="#rid3">3-8</a>]. In the United States, Hispanic Americans were not found to have greater lifetime incidence rates of APL than White Americans, although the incidence rates for APL were higher among Hispanic children and young adults [<a href="#rid5">5</a>]. Black Americans had lower lifetime incidence rates than non-Hispanic White, Hispanic, and Asian Americans [<a href="#rid3">3-7</a>]. Various studies have reported a modest increase in the incidence of APL in the last two decades [<a href="#rid7">7,9</a>]. The cause for this increased incidence remains unknown.</p><p>The age distribution of patients with APL differs from other forms of AML. APL is uncommon in the first decade of life; its incidence increases during the second decade to reach a plateau during early adulthood, and then remains constant until it decreases after age 60 years [<a href="#rid10">10</a>]. Incidence does not vary by sex. Increased risk for APL has been associated with elevated body mass index (BMI) [<a href="#rid11">11</a>].</p><p>APL can sometimes occur after cytotoxic therapy for another disease (eg, breast cancer, lymphoma, other solid tumors), especially in association with the use of topoisomerase-II inhibitors such as <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, or after radiation therapy [<a href="#rid12">12</a>]. APL has been observed in patients with multiple sclerosis who have been treated with <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>, another topoisomerase II inhibitor. Therapy-related AML is presented separately. (See  <a class="medical medical_review" href="/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities", section on 'Therapy-related myeloid neoplasms'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H4"><span class="h2">General features</span><span class="headingEndMark"> — </span>Patients with acute myeloid leukemia (AML) in general, and APL in particular, typically present with symptoms related to complications of pancytopenia (ie, anemia, neutropenia, and thrombocytopenia), including weakness and easy fatigability, infections of variable severity, and/or hemorrhagic findings such as gingival bleeding, ecchymoses, epistaxis, or menorrhagia. Combinations of these symptoms are common. Unique to APL is a presentation with bleeding secondary to disseminated intravascular coagulation, which is discussed below. (See  <a class="medical medical_review" href="/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Clinical presentation'</a>.)</p><p>Patients with APL, particularly the hypergranular variant, can have a low white cell count and only rare leukemic cells in the peripheral blood. Although APL is not usually a rapidly proliferative acute leukemia, by the time that patients present with symptoms, the situation has often become a life-threatening emergency because of the risk of catastrophic bleeding. How long APL is typically present in its preclinical phase is not known, but at diagnosis the marrow is often nearly 100 percent replaced by malignant promyelocytes, leading to severe anemia, thrombocytopenia, and neutropenia. Only a small number of APL cells may be present in the blood. More importantly, this mass of malignant cells in the marrow provokes a severe coagulopathy with both disseminated intravascular thrombosis and primary fibrinolysis. The variant of APL characterized by microgranular APL cells does not bear any additional independent prognostic value, but tends to present with higher peripheral blast counts and perhaps more rapid proliferation. A white blood cell count &gt;10,000/microL (&gt;10 x 10<sup>9</sup>/L) at diagnosis identifies a high-risk subset of APL, due in part to a higher early death rate.</p><p class="headingAnchor" id="H5"><span class="h2">Coagulopathy and APL</span><span class="headingEndMark"> — </span>Coagulopathy associated with APL is complex and involves both disseminated intravascular coagulation (DIC) and primary hyperfibrinolysis and is either present at diagnosis or occurs soon after the initiation of cytotoxic chemotherapy [<a href="#rid13">13</a>]. This complication constitutes a medical emergency, because, if left untreated, it can cause pulmonary or cerebrovascular hemorrhage in up to 40 percent of patients and a 10 to 20 percent incidence of early hemorrhagic death [<a href="#rid14">14-18</a>]. Thrombotic complications are less common. (See <a class="local">'Microgranular variant'</a> below and  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism</strong> – The mechanism of the complex coagulopathy in APL is incompletely understood. However, the following factors may be of primary importance [<a href="#rid13">13,15</a>]. (See  <a class="medical medical_review" href="/d/html/1353.html" rel="external">"Cancer-associated hypercoagulable state: Causes and mechanisms"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tissue factor (TF), which forms a complex with factor VII to activate factors X and IX. The rearranged <em>RARA</em> in APL activates the TF promoter and increases its expression in the leukemic cells resulting in a procoagulant state. TF expression can also be upregulated by cells undergoing apoptosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Death of APL cells by ETosis (a death pathway distinct from apoptosis and necrosis) releases extracellular chromatin and phosphatidylserine, which contribute to a hypercoagulable state by increasing thrombin generation and fibrin formation, damaging endothelial cells and converting them to a procoagulant phenotype, and increasing plasmin generation [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary hyperfibrinolysis is a result of expression of annexin II, tissue and urokinase plasminogen activator as well as an acquired deficiency of alpha-2 antiplasmin and plasminogen activator inhibitor-1. Annexin II expression is increased on the surface of the leukemic promyelocytes [<a href="#rid20">20</a>]. Annexin II binds plasminogen and its activator, tissue plasminogen activator, increasing plasmin formation by a factor of 60.</p><p></p><p>The induction of tumor cell differentiation with retinoic acid, plus appropriate supportive therapy, can lead to rapid improvement in the coagulopathy primarily by reducing the hypercoagulable state but with little effect on the hyperfibrinolytic pathway. (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults", section on 'Control of coagulopathy'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOLOGIC FEATURES</span></p><p class="headingAnchor" id="H7"><span class="h2">Morphology</span><span class="headingEndMark"> — </span>A significant number of patients will present with low white cell count at the time of diagnosis with only rare leukemic cells in the peripheral blood. In addition, the microgranular variant can be easily confused with myeloid leukemia with monocytic differentiation. A careful evaluation of the peripheral blood smear and recognition of the classic and variant morphology is therefore critical in making a presumptive diagnosis of APL before the molecular/cytogenetic data become available. </p><p>APL is characterized by the presence of atypical promyelocytes in the bone marrow and peripheral blood. Promyelocytes are large (usually &gt;20 microns in diameter) myeloid precursors with variable morphology. Often there is a high nucleus to cytoplasmic ratio, fine chromatin, and prominent nucleoli. The cardinal feature of the promyelocyte is the presence of many violet granules in the cytoplasm with either a dense or coarse pattern, often obscuring the nucleus. The cells of APL differ morphologically from those of normal promyelocytes in that they are larger and typically have creased, folded, bilobed, kidney-shaped, or dumb-bell shaped nuclei (<a class="graphic graphic_picture graphicRef82863" href="/d/graphic/82863.html" rel="external">picture 1</a>) [<a href="#rid21">21</a>].</p><p>There are two morphologic variants of APL: the hypergranular form and the microgranular form. Clinicians should be aware of these morphologic variants to allow for the identification of potential cases and the rapid initiation of treatment when the diagnosis is suspected. (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.) </p><p class="headingAnchor" id="H8"><span class="h3">Hypergranular form</span><span class="headingEndMark"> — </span>The hypergranular, or "typical," form of APL is the most common variant, accounting for approximately 75 percent of cases [<a href="#rid21">21</a>]. On Wright-stained smears, the cytoplasm of these promyelocytes typically contains densely-packed bright pink, reddish-blue, or dark purple granules (<a class="graphic graphic_picture graphicRef82863" href="/d/graphic/82863.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef82864" href="/d/graphic/82864.html" rel="external">picture 2</a>). Neoplastic promyelocytes frequently contain Auer rods or occasionally bundles of Auer rods (<a class="graphic graphic_picture graphicRef82866" href="/d/graphic/82866.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef82865" href="/d/graphic/82865.html" rel="external">picture 4</a>). </p><p class="headingAnchor" id="H9"><span class="h3">Microgranular variant</span><span class="headingEndMark"> — </span>The microgranular (hypogranular) variant accounts for approximately 25 percent of cases [<a href="#rid22">22</a>]. The cells in this variant typically have a bilobed nucleus and no apparent granules on light microscopy (<a class="graphic graphic_picture graphicRef82867" href="/d/graphic/82867.html" rel="external">picture 5</a>). Primary granules are present, however, and are easily demonstrated using electron microscopy [<a href="#rid23">23</a>]. The hypogranular promyelocytes can sometimes be mistakenly identified as being of monocytic origin. However, in contrast to monocytes, the myeloperoxidase reaction is strongly positive, and the non-specific esterase reaction is negative or only weakly positive.</p><p>In a typical case of APL, the malignant promyelocytes usually account for 30 percent or more of the myeloid cells in the bone marrow and are considered equivalent to blasts. Sometimes there are also increased blasts, but there are very few cells that mature past the promyelocyte stage of differentiation. The abnormal promyelocytes are usually intensely myeloperoxidase reaction positive. The non-specific esterase reaction is weakly positive in a quarter of cases but should not be construed as evidence of monocyte differentiation. Monocytes show bright non-specific esterase reactivity.</p><p class="headingAnchor" id="H11"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>Typically, APL cells share certain immunophenotypic features with their normal promyelocytic counterparts [<a href="#rid6">6,21</a>]. The hypergranular variants have a high side scatter; express bright cytoplasmic myeloperoxidase, CD13 and CD33; are partial, weak, or negative for CD34; and do not express or only dimly express HLA-DR and CD11b. In contrast to normal promyelocytes, APL cells express abnormally low levels of CD15 and weak or variable CD117. </p><p>The hypogranular variant of APL shows a similar phenotype with a comparably bright myeloperoxidase expression and frequent coexpression of CD2, and can sometimes express CD34. Some cases can also show CD56, and this has been reported to be associated with worse prognosis [<a href="#rid24">24</a>]. Thus, with the caveats noted above, the APL phenotype is considered CD34 negative/partial or weak positive, HLA-DR negative, CD13 positive, CD33 positive, CD11b negative, CD15 weak or negative, CD117 weak/variable, and sometimes CD2 positive and CD56 positive.</p><p>Immunostaining with anti-PML monoclonal antibodies is a somewhat specific test that can be performed in as little as two to four hours [<a href="#rid25">25</a>]. APL demonstrates a microspeckled nuclear staining pattern with nucleolar exclusion that differs from the discrete larger and fewer nuclear dots seen in normal cells and other forms of acute myeloid leukemia (AML) (<a class="graphic graphic_picture graphicRef82868" href="/d/graphic/82868.html" rel="external">picture 6</a>). Sometimes, however, the staining pattern of non-APL cases can be difficult to interpret.</p><p>Furthermore, additional accompanying acquired mutations in particular genes such as <em>FLT3</em>-ITD (fms-like tyrosine kinase-internal tandem duplications) may be present as well although their prognostic significance for the time being is not certain and may differ by age [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Genetic features</span><span class="headingEndMark"> — </span>APL with t(15;17)(q24.1;q21.2);<em>PML::RARA</em> is defined by the presence of a reciprocal translocation between the long arms of chromosomes 15 and 17, with the creation of a fusion gene, <em>PML::RARA</em> which links the retinoic acid receptor alpha (<em>RARA</em>) gene on chromosome 17 with the promyelocytic leukemia (<em>PML</em>) gene on chromosome 15 [<a href="#rid28">28-30</a>]. (See  <a class="medical medical_review" href="/d/html/4523.html" rel="external">"Molecular biology of acute promyelocytic leukemia"</a>.)</p><p>Of importance, some differences exist regarding the precise location of the translocation breakpoints depending on whether banded chromosomes are studied by light microscopy or the genetic loci by molecular studies. By chromosomal banding the translocation has been noted as t(15;17)(q22;q12), but based on the human genome sequence, the translocation is now believed to be more precisely written as t(15;17)(q24.1;q21.2). Rare cases of APL are associated with variant translocations/gene rearrangements. (See <a class="local">'Variant RARA translocations'</a> below.) </p><p>The genetic abnormality may be detected using the following techniques, each of which has advantages and disadvantages [<a href="#rid6">6</a>]. Bone marrow samples are preferred for each technique:</p><p class="headingAnchor" id="H13"><span class="h3">Conventional karyotype</span><span class="headingEndMark"> — </span>This method is highly specific, and an essential part of the standard workup, but it is time-consuming, usually taking approximately two days for results. Cryptic rearrangements leading to <em>PML::RARA</em> fusion will be missed (false negatives). However, rare molecular subtypes of APL, such as t(11;17), t(5;17), and other additional coexistent cytogenetic abnormalities can be detected.</p><p class="headingAnchor" id="H14"><span class="h3">Fluorescence in situ hybridization</span><span class="headingEndMark"> — </span>Fluorescence in situ hybridization (FISH) for the <em>PML::RARA</em> fusion is less expensive and quicker than conventional cytogenetics. The sensitivity varies depending on the probe used. FISH does not provide information about the <em>PML::RARA</em> isoform detected and therefore cannot be used for the molecular monitoring of residual disease. FISH can be performed usually within 24 hours or, in some instances, in an even shorter time.</p><p class="headingAnchor" id="H15"><span class="h3">Reverse transcriptase polymerase chain reaction</span><span class="headingEndMark"> — </span>Reverse transcriptase polymerase chain reaction (RT-PCR) for <em>PML::RARA</em> RNA is considered by many to be the current "gold standard" method for confirming the diagnosis of APL. RT-PCR also provides information on the PML breakpoint location, which can be used for monitoring measurable residual disease (MRD; also referred to as minimal residual disease). However, RT-PCR can have both false-positives (contamination artifacts) and false-negatives (due to poor RNA yield). (See  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H1490591368"><span class="h3">Variant <i>RARA </i>translocations</span><span class="headingEndMark"> — </span>Multiple variant translocations involving the <em>RARA</em> gene on chromosome 17 have been described. These cases can have morphologic features that overlap with APL. However, because of variation in biology as well as differences in response to pharmacologic doses of ATRA, these cases have been reclassified in the current World Health Organization system as "APL with a variant <em>RARA</em> translocation" [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/4523.html" rel="external">"Molecular biology of acute promyelocytic leukemia", section on 'Variant translocations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>t(11;17)(q23;q21) – <em>ZBTB16::RARA </em>(previously known as <em>PLZF::RARA</em>), often CD13+, CD56+</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>t(5;17)(q35;q21) – <em>NPM1::RARA</em>, often CD13-negative, CD56-negative</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>t(11;17)(q13;q21) – <em>NuMA::RARA</em></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>t(17;17)(q21;q21) – <em>STAT5b::RARA</em></p><p></p><p>Cells with the variant translocation t(11;17) tend to have nuclei that are more regular in outline, with an increased number of maturing neutrophils with hypolobulation (ie, acquired Pelger-Huet anomaly). These cases have features intermediate between AML with maturation and APL, with sparser granules, lack of "faggot" cells, and absence of the typical bilobed nucleus seen in the typical forms of APL [<a href="#rid21">21,32,33</a>]. The <em>ZBTB16::RARA</em> fusion protein that is produced in this chromosomal rearrangement shows reduced sensitivity to retinoic acid that cannot be overcome by pharmacologic doses of ATRA [<a href="#rid28">28,34</a>].</p><p class="headingAnchor" id="H17"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>APL represents a medical emergency with a high rate of early mortality, often due to hemorrhage from a characteristic coagulopathy. It is strongly recommended to start treatment with a differentiation agent (eg, tretinoin, also known as <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> or ATRA) without delay as soon as the diagnosis is suspected based on cytologic and clinical criteria, and before definitive genetic, cytogenetic, or immunostaining confirmation of the diagnosis has been made. If the diagnosis is not confirmed, ATRA can be discontinued and treatment changed to that used for other types of acute myeloid leukemia (AML). (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p>The diagnosis of APL is suspected by the characteristic morphology of the leukemic cells, immunophenotype, or the presence of severe coagulopathy as described above. Another diagnostic clue is that the non-microgranular form of APL often presents with leukopenia. The diagnosis is confirmed by the identification of the <em>PML::RARA</em> fusion gene and/or the associated chromosomal translocation (or one of the rare variants described above). While all available diagnostic tools should be utilized, a request for an expedited molecular/FISH analysis looking for <em>PML::RARA</em> generally provides the fastest diagnostic result. This genetic confirmation serves to differentiate APL from other forms of acute leukemia.</p><p class="headingAnchor" id="H18"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Without treatment, APL has a very short median survival of less than one month resulting from uncontrolled bleeding. However, with modern therapy, APL is associated with the highest proportion of patients who are presumably cured of their disease. Despite the overall good prognosis for this group of patients, there is heterogeneity in this population. Patients younger than age 30 years and those who present with a white blood cell (WBC) count less than 10,000/microL (10 x 10<sup>9</sup>/L) have superior event-free survival [<a href="#rid35">35</a>]. In contrast to other types of acute myeloid leukemia (AML), age over 60 years is not a predictor of poor results in APL [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/86177.html" rel="external">"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults", section on 'Prognosis'</a>.)</p><p>In a multivariate analysis of 217 patients with newly diagnosed <em>PML::RARA</em>-positive APL treated in the Italian GIMEMA and the Spanish PETHEMA trials, adverse risk factors were a total WBC count greater than 10,000/microL and a platelet count less than or equal to 40,000/microL [<a href="#rid37">37</a>]. Using these two parameters, three prognostic categories could be distinguished, with the following estimated probabilities of three-year relapse-free survival (RFS):</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk – WBC ≤10,000/microL and platelets &gt;40,000/microL; RFS 98 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate – WBC ≤10,000/microL and platelets ≤40,000/microL; RFS 89 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk – WBC &gt;10,000/microL; RFS 70 percent</p><p></p><p>These three risk groups originally proposed by the PETHEMA group can be collapsed into two groups based entirely on the WBC count (≤10,000 or &gt;10,000/microL at diagnosis) [<a href="#rid38">38,39</a>]. That is, the platelet count is not necessary to distinguish a low/intermediate risk group when <a class="drug drug_general" data-topicid="8977" href="/d/drug information/8977.html" rel="external">arsenic trioxide</a> (ATO) is used early in therapy. Studies have demonstrated that patients in this risk group have superior outcome when treated with ATRA plus ATO in comparison to ATRA plus anthracycline-based chemotherapy [<a href="#rid40">40</a>]. </p><p>Up to 40 percent of patients will have chromosomal abnormalities in addition to t(15;17). There is no evidence that additional cytogenetic abnormalities or molecular aberrations (eg, <em>FLT3-</em>ITD [Fms-like tyrosine kinase-3 receptor] gene mutations) have an adverse effect on prognosis [<a href="#rid41">41-44</a>]. In two large studies of patients treated with an anthracycline plus <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> or with <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) and chemotherapy, additional chromosomal abnormalities had no impact on prognosis [<a href="#rid43">43,44</a>]. </p><p>Internal tandem duplications in the <em>FLT3</em>-ITD gene are frequently seen in APL. They are associated with an increased WBC count at diagnosis but do not add unambiguous independent prognostic value. (See  <a class="medical medical_review" href="/d/html/4516.html" rel="external">"Acute myeloid leukemia: Risk factors and prognosis"</a>.)</p><p class="headingAnchor" id="H430481923"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117352.html" rel="external">"Society guideline links: Acute promyelocytic leukemia"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Acute promyelocytic leukemia (APL) is a biologically and clinically distinct category of acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. APL represents a medical emergency with a high rate of early mortality that requires initiation of treatment as soon as the diagnosis is suspected (ie, even before genetic confirmation of the diagnosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – APL accounts for 5 to 20 percent of AML. It is uncommon in the first decade of life, the incidence increases during early adulthood and it remains at a plateau until it decreases after age 60 years. (See <a class="local">'Epidemiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – APL most often presents with weakness/fatigue from anemia, infections due to neutropenia, and/or hemorrhage due to thrombocytopenia or disseminated intravascular coagulation (DIC). (See <a class="local">'Clinical features'</a> above.)  </p><p></p><p class="bulletIndent1">DIC, which is often present at diagnosis, requires emergency therapy. (See <a class="local">'Coagulopathy and APL'</a> above and  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults", section on 'Control of coagulopathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Characteristic malignant promyelocytes are present in blood and marrow.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Blood</strong> – Atypical promyelocytes, which are large myeloid precursors with variable morphology, are seen on blood smear. </p><p></p><p class="bulletIndent2">There are two categories of APL:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hypergranular APL</strong> – The cardinal feature is numerous violet cytoplasmic granules with a dense or coarse pattern that often obscures the nucleus (<a class="graphic graphic_picture graphicRef82863" href="/d/graphic/82863.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef82864" href="/d/graphic/82864.html" rel="external">picture 2</a>); malignant promyelocytes often contain Auer rods (<a class="graphic graphic_picture graphicRef82866" href="/d/graphic/82866.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef82865" href="/d/graphic/82865.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Microgranular variant</strong> – One-quarter of cases correspond to the microgranular variant of APL, in which malignant promyelocytes have a bilobed nucleus and no apparent granules on light microscopy (<a class="graphic graphic_picture graphicRef82867" href="/d/graphic/82867.html" rel="external">picture 5</a>); the promyelocytes may be resemble monocytic cells. </p><p></p><p class="bulletIndent2">Patients with APL, particularly the hypergranular variant, can have a low white cell (WBC) count at diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow</strong> – Infiltration of marrow by malignant promyelocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Most (≥95 percent) cases of APL have the t(15;17)(q24.1;q21.2) chromosomal translocation, which is associated with <em>PML::RARA</em> fusion gene that links retinoic acid receptor alpha (<em>RARA</em>) on chromosome 17 with the promyelocytic leukemia (<em>PML</em>) gene on chromosome 15. (See <a class="local">'Genetic features'</a> above.)</p><p></p><p class="bulletIndent1">Rare APL variants include: t(11;17)/<em>ZBTB16::RARA</em>, t(5;17)/<em>NPM1::RARA</em>, t(11;17)/<em>NuMA::RARA</em>, and t(17;17)/<em>STAT5b::RARA</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype </strong>– Malignant cells typically express CD13 and CD33, are usually negative or weakly positive for CD34, and do not express or only dimly express CD15, CD117, HLA-DR, and CD11b. (See <a class="local">'Immunophenotype'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of APL is confirmed by detection of <em>PML::RARA</em> by reverse transcriptase polymerase chain reaction (RT-PCR) or the associated translocation t(15;17) chromosomal translocation by conventional cytogenetics or fluorescence in situ hybridization (FISH). Some cases have cytogenetic or molecular findings associated with a rare variant of APL. (See <a class="local">'Genetic features'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Treatment with <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (ATRA) should be initiated when the diagnosis of APL is suspected by the clinical presentation, morphology, cytochemistry, and/or flow cytometry, even before genetic confirmation of the diagnosis. (See  <a class="medical medical_review" href="/d/html/4498.html" rel="external">"Initial treatment of acute promyelocytic leukemia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3395066182"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The<strong> </strong>UpToDate editorial staff acknowledges John Anastasi, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li><li><a class="nounderline abstract_t">Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008; 19:379.</a></li><li><a class="nounderline abstract_t">Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.</a></li><li><a class="nounderline abstract_t">Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 2006; 15:367.</a></li><li><a class="nounderline abstract_t">Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875.</a></li><li><a class="nounderline abstract_t">Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer 2012; 118:5811.</a></li><li><a class="nounderline abstract_t">Douer D. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16:357.</a></li><li><a class="nounderline abstract_t">Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011; 118:1248.</a></li><li><a class="nounderline abstract_t">Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia 2000; 14:722.</a></li><li><a class="nounderline abstract_t">Kashanian SM, Li AY, Mustafa Ali M, et al. Increased body mass index is a risk factor for acute promyelocytic leukemia. EJHaem 2021; 2:33.</a></li><li><a class="nounderline abstract_t">Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003; 21:2123.</a></li><li><a class="nounderline abstract_t">Mantha S, Tallman MS, Soff GA. What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia? Curr Opin Hematol 2016; 23:121.</a></li><li><a class="nounderline abstract_t">Warrell RP Jr, de Thé H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329:177.</a></li><li><a class="nounderline abstract_t">Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093.</a></li><li><a class="nounderline abstract_t">Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543.</a></li><li><a class="nounderline abstract_t">Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82:3241.</a></li><li><a class="nounderline abstract_t">Rodeghiero F, Avvisati G, Castaman G, et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75:2112.</a></li><li><a class="nounderline abstract_t">Cao M, Li T, He Z, et al. Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. Blood 2017; 129:1855.</a></li><li><a class="nounderline abstract_t">Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.</a></li><li><a class="nounderline abstract_t">Sainty D, Liso V, Cantù-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Blood 2000; 96:1287.</a></li><li><a class="nounderline abstract_t">McKenna RW, Parkin J, Bloomfield CD, et al. Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant. Br J Haematol 1982; 50:201.</a></li><li><a class="nounderline abstract_t">Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76:827.</a></li><li><a class="nounderline abstract_t">Montesinos P, Rayón C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 2011; 117:1799.</a></li><li><a class="nounderline abstract_t">Dimov ND, Medeiros LJ, Kantarjian HM, et al. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 2010; 116:369.</a></li><li><a class="nounderline abstract_t">Poiré X, Moser BK, Gallagher RE, et al. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma 2014; 55:1523.</a></li><li><a class="nounderline abstract_t">Kutny MA, Moser BK, Laumann K, et al. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59:662.</a></li><li><a class="nounderline abstract_t">Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93:3167.</a></li><li><a class="nounderline abstract_t">Kakizuka A, Miller WH Jr, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 1991; 66:663.</a></li><li><a class="nounderline abstract_t">Jimenez JJ, Chale RS, Abad AC, Schally AV. Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget 2020; 11:992.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a class="nounderline abstract_t">Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85:1083.</a></li><li><a class="nounderline abstract_t">Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood 2000; 96:1297.</a></li><li><a class="nounderline abstract_t">Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91:2634.</a></li><li><a class="nounderline abstract_t">Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16:78.</a></li><li><a class="nounderline abstract_t">Latagliata R, Avvisati G, Lo Coco F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged &gt; 60 years. Ann Oncol 1997; 8:1273.</a></li><li><a class="nounderline abstract_t">Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96:1247.</a></li><li><a class="nounderline abstract_t">Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116:3751.</a></li><li><a class="nounderline abstract_t">Osman AEG, Anderson J, Churpek JE, et al. Treatment of Acute Promyelocytic Leukemia in Adults. J Oncol Pract 2018; 14:649.</a></li><li><a class="nounderline abstract_t">Platzbecker U, Avvisati G, Cicconi L, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 2017; 35:605.</a></li><li><a class="nounderline abstract_t">Hiorns LR, Swansbury GJ, Mehta J, et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96:314.</a></li><li><a class="nounderline abstract_t">Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.</a></li><li><a class="nounderline abstract_t">Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15:1786.</a></li><li><a class="nounderline abstract_t">De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000; 111:801.</a></li></ol></div><div id="topicVersionRevision">Topic 4527 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18064533" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835508" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18812465" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22707337" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12935956" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The epidemiology of acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21653939" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764161" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693438" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increased body mass index is a risk factor for acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775738" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Therapy-related acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26760586" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : What's new in the pathogenesis of the coagulopathy in acute promyelocytic leukemia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515790" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9558362" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732003" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8241496" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189506" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28053193" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10099141" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Annexin II and bleeding in acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942370" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6949609" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute promyelocytic leukaemia: a study of 39 cases with identification of a hyperbasophilic microgranular variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6586073" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148082" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19950129" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24160850" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22378655" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233871" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1652368" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32215187" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute promyelocytic leukemia (APL): a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849296" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942371" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531570" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440726" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9496395" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged&gt;60 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10942364" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20705755" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30423270" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of Acute Promyelocytic Leukemia in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27400939" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9029019" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746770" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164186" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122141" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
